Life science investors close nearly $6 billion in new funds; Nostrum Laboratories and its CEO to pay up to $50 million over Medicaid rebates

Taking stock of the drug industry, from the lab to the medicine chest

November 1, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Life science investors close nearly $6 billion in new funds One of the latest announcements, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. By Allison DeAngelis STAT+ | Nostrum Labs and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates Nostrum Laboratories CEO Nirmal Mulye once said he had "a moral requirement to make money sell the product at the highest price." By Ed Silverman Opinion: How the government can help lower the price — not just the cost — of cutting-edge gene therapies The high cost of gene therapies doesn't just limit access to these medicines — it also stunts work toward future cures and treatments. By Vivian G. Cheung Courtesy Google DeepMind STAT+ | DeepMind touts AlphaFold's new skills as protein-folding AI models face off AlphaFold now has capabilities crucial to drug development: Computational biology advance based on predicting protein sequences. By Katie Palmer and Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser